So, here's a fun twist in the weight-loss drug wars: Novo Nordisk (NVO) might have a new contender that could outshine its own current star. The company, along with its partner United Laboratories International Holdings Limited, reported topline data Wednesday from a Phase 2 trial in China for an experimental drug called UBT251. The early read? It appears to cut blood sugar levels and weight more than semaglutide, the key ingredient in the famed Wegovy and Ozempic.
Think of it as a company potentially competing with its own blockbuster. UBT251 is a triple receptor agonist—it targets GLP-1, GIP, and glucagon receptors. That puts it squarely in the growing class of multi-agonist therapies designed to challenge drugs like Eli Lilly & Co.'s (LLY) 'Triple G' obesity drug, retatrutide, which has already shown promising weight loss results. This candidate is being co-developed by United Bio-Technology and Novo Nordisk under a March 2025 agreement, where United leads development in mainland China, Hong Kong, Macau, and Taiwan, while Novo Nordisk handles the global markets.
Now, let's talk numbers, because that's where it gets interesting. In the 24-week study, patients on the once-weekly injectable UBT251 achieved a maximum mean HbA1c (a measure of blood sugar) reduction of 2.16% from a baseline of 8.12%. For comparison, semaglutide 1 mg led to a 1.77% reduction, and placebo was at 0.66%. On the weight loss front, from a baseline of 80.1 kg, patients on UBT251 saw reductions of up to 9.8%. That stacks up against 4.8% with semaglutide and 1.4% with placebo. So, in this early look, the new drug is showing a meaningful edge.
But it wasn't just about sugar and weight. UBT251 also demonstrated improvements in secondary endpoints like waist circumference, blood pressure, and lipid levels compared to placebo. The safety and tolerability profile was consistent with what's been seen in prior studies of triple agonists, with no unexpected findings—which is always good news in drug development.
What's next? Well, this is just the beginning. Novo Nordisk has already kicked off a global Phase 1b/2a trial evaluating UBT251 in overweight participants, with results expected in 2027. The company also plans to start a global Phase 2 trial in type 2 diabetes in the second half of 2026. Meanwhile, United Biotechnology intends to push forward locally, with plans to launch two Phase 3 trials in Chinese patients. Detailed data from this current study will be presented at a medical conference later this year, giving a fuller picture.
As for the market's immediate reaction? Novo Nordisk shares were up 0.89% at $37.22 at the last check on Wednesday, according to market data.
